{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:58:24Z","timestamp":1780513104762,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.leukres.2008.11.031","type":"journal-article","created":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T19:20:22Z","timestamp":1232565622000},"page":"1047-1054","source":"Crossref","is-referenced-by-count":12,"title":["Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"33","author":[{"given":"Ingrid","family":"Th\u00f6rn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hermansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudmar","family":"L\u00f6nnerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Barbany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.11.031_bib1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(01)00516-2","article-title":"Childhood acute lymphoblastic leukaemia\u2014current status and future perspectives","volume":"2","author":"Pui","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2008.11.031_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of acute lymphoblastic leukemia","volume":"354","author":"Pui","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.11.031_bib3","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/sj.leu.2401961","article-title":"Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO)","volume":"14","author":"Gustafsson","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbmt.2006.09.013","article-title":"Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: a children's oncology group study report","volume":"13","author":"Satwani","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.leukres.2008.11.031_bib5","first-page":"382","article-title":"Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology","volume":"90","author":"Cazzaniga","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.11.031_bib6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2008.11.031_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib8","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.031_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukaemia. European Organization for Research and Treatment of Cancer\u2014Childhood Leukemia Cooperative Group","volume":"339","author":"Cave","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.11.031_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2008.5","article-title":"Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia","volume":"22","author":"Flohr","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pbc.20794","article-title":"Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia","volume":"48","author":"Sramkova","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.leukres.2008.11.031_bib12","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","article-title":"Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia","volume":"92","author":"Knechtli","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.031_bib13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2141.2002.03838.x","article-title":"Prospective molecular monitoring of BCR\/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response","volume":"119","author":"Cazzaniga","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.11.031_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.leu.2401279","article-title":"Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL","volume":"13","author":"Lucio","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/sj.leu.2402150","volume":"15","author":"Lucio","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib16","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/sj.leu.2401246","article-title":"Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes","volume":"12","author":"Pongers-Willemse","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2401245","volume":"13","author":"Pongers-Willemse","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib18","first-page":"63","article-title":"Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group","volume":"96","author":"Willems","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.031_bib19","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/sj.leu.2400887","article-title":"Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations","volume":"11","author":"Langerak","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib20","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/sj.leu.2401801","article-title":"Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia","volume":"14","author":"Verhagen","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib21","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/sj.leu.2402515","article-title":"T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/sj.leu.2402475","article-title":"Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR","volume":"16","author":"van der Velden","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood.V98.8.2456","article-title":"Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells","volume":"98","author":"Langerak","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.031_bib24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib26","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib27","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib28","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molec- ular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib29","first-page":"3171","article-title":"LightCycler technology for the quantitation of bcr\/abl fusion transcripts","volume":"59","author":"Kreuzer","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.11.031_bib30","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/sj.leu.2403983","article-title":"Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL","volume":"19","author":"Gruber","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2005.05611.x","article-title":"Philadelphia positive acute lymphoblastic leukaemia of childhood","volume":"130","author":"Jones","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.11.031_bib32","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.leu.2404603","article-title":"Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?","volume":"21","author":"Szczepanski","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V99.7.2315","article-title":"Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease","volume":"99","author":"Szczepanski","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.11.031_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.leu.2401970","article-title":"Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that grow out during relapse already have the slowest rate of reduction during induction therapy","volume":"15","author":"de Haas","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib35","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/0008-5472.CAN-04-1356","article-title":"Leukemic stem cells in childhood high-risk ALL\/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19\u2212 cells","volume":"65","author":"Hotfilder","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.11.031_bib36","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","article-title":"Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL","volume":"16","author":"Bader","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cancergencyto.2006.11.021","article-title":"Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript","volume":"174","author":"Pienkowska-Grela","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.leukres.2008.11.031_bib38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajh.10456","article-title":"Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory","volume":"75","author":"Snyder","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2008.11.031_bib39","first-page":"457","article-title":"bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient","volume":"5","author":"van der Plas","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib40","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.2000.02471.x","article-title":"Are aberrant BCR\u2014ABL transcripts more common than previously thought?","volume":"111","author":"Wilson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.11.031_bib41","first-page":"397","article-title":"A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Soekarman","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib42","first-page":"1696","article-title":"Heterogeneity of the breakpoint in the ABL gene in cases with BCR\/ABL transcript lacking ABL exon a2","volume":"8","author":"Iwata","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.11.031_bib43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3324\/haematol.11737","article-title":"Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia","volume":"92","author":"Burmeister","year":"2007","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608005298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T22:17:51Z","timestamp":1589494671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608005298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0145212608005298"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.11.031","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}